Other languages OKYO Pharma Limited

Equities

EMMLD

GG00BMFG5F62

Market Closed - Nasdaq Other stock markets 02:00:00 14/06/2024 am IST			5-day change	1st Jan Change
1.36 ^USD	+3.05%		+1.50%	-23.16%

22/03	H.C. Wainwright Adjusts Price Target on OKYO Pharma to $7 From $6, Maintains Buy Rating	MT
22/03	OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101	22/03
OKYO Pharma Limited to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial	20/03
Sector Update: Health Care Stocks Mixed in Afternoon Trading	10/02
Sector Update: Health Care	10/02
OKYO Pharma Rising After FDA Approves Phase 2 Trial of Prospective Treatment for Cornea Eye Pain	09/02
Okyo Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain	09/02
OKYO Pharma Limited Announces Appointment of Scientific Advisory Board	31/01
OKYO Pharma Limited Reports Positive Safety and Efficacy Results in Its Phase 2, Randomized, Double-Masted, Placebo-Controlled Trial Evaluating the Safety and Efficacy of OK-101 Ophthalmic Solution in Patients with Dry Eye Disease	08/01
Okyo Pharma Limited Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit	04/12
Sector Update: Health Care Stocks Lean Lower Premarket Monday	09/23/09
OKYO Pharma Submits Investigational New Drug Application for OK-101 in Neuropathic Corneal Pain	09/23/09
Okyo Pharma Limited Announces Filing of an Investigational New Drug Application for Ok-101 to Treat Neuropathic Corneal Pain	09/23/09
OKYO Pharma Limited Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease	05/23/05
Traders Digest Fresh Batch of Data, Stifling US Equity Futures Pre-Bell	15/23/15
Top Premarket Decliners	15/23/15
Sector Update: Health Care Stocks Rising Late Afternoon	15/23/15
Sector Update: Health Care Stocks Rising in Afternoon Trading	14/23/14
OKYO Pharma Prices $4 Million Share Offering	14/23/14
Top Premarket Decliners	14/23/14
OKYO Pharma Plans Share Offering; Stock Down After-Hours	14/23/14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages OKYO Pharma Limited

Equities

EMMLD

GG00BMFG5F62

Other languages

Filters